AGT and diabetic kidney disease: Similarly, the data from the RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) [33] and IDNT (Irbesartan Diabetic Nephropathy Trial) [34] trials confirmed the nephroprotective effect of ARBs, in patients with DKD with proteinuria.